Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β₂ agonist; pMDI, pressurised metered-dose inhaler; SABA, short-acting β₂ agonist
Discover flutiform® pMDI
flutiform® pMDI is a fixed-dose combination of a potent inhaled corticosteroid steroid (ICS), fluticasone propionate, and formoterol fumarate – a fast-acting LABA. It is indicated in the regular treatment of asthma where the use of a combination product is appropriate:5
- For patients not adequately controlled with an ICS and ‘as required’ inhaled SABA.5
- For patients already adequately controlled on an ICS and a LABA.5
5 things you need to know about flutiform® pMDI
flutiform® pMDI has demonstrated improved asthma control compared to baseline, and low incidence of severe asthma exacerbations across randomised controlled trials (2.1%)4 and different real-world evidence studies2-3
1
Improved asthma control across different real-world evidence studies1-3
- More than 4,000 patients were enrolled in real-world evidence studies over 3 and 12 months1-3
- ffLUX Study1^
- ffAIRNESS Study2¶
- AffIRM Study3#
2
Warmer, less forceful plume vs fluticasone propionate/ salmeterol pMDI6
- Which may reduce the amount of drug deposition at the back of the throat and lead to improved lung deposition.6
5
Low incidence of severe asthma exacerbations4*
- Long-term flutiform® pMDI therapy is associated with a low rate of severe asthma exacerbations (2.1%).4*
Click the link below to find out more information on tolerability.
4
Fast-acting LABA5†
- Onset of bronchodilation within 1-3 min.5†
†flutiform® inhaler is not indicated for use as a reliever.5
3
High lung deposition throughout both central and peripheral airways:7‡
The mean drug deposition fractions and standard deviations (SDs) in the entire lung:
- ICS: 46.18% ± 1.29%,
- LABA: 44.34% ± 1.23%
The mean drug deposition fractions and standard deviations (SDs) in the peripheral airways:
- ICS: 30.33% ± 1.89%
- LABA: 29.17% ± 1.81%
*Pooled exacerbation rate from two open-label studies with fixed dose flutiform® pMDI administered for between 26 to 60 weeks in adults and adolescents with asthma (95% CI: 1.1, 3.2%). Exacerbations treated with an oral, intramuscular, or intravenous corticosteroid.4
‡In an in-vitro lung deposition study, using Functional Respiratory Imaging, flutiform® pMDI 125/5 μg was tested at an inspiratory flow rate of 30 L/min.7
§Based on Asthma Control Test score ≥ 20.2,3
^A significantly higher proportion of patients achieved controlled asthma after switching from fluticasone propionate/ salmeterol pMDI to flutiform® pMDI.1
¶The percentage of patients with well-controlled asthma more than doubled, from 30.9% to 65.3%, after 12 months.2
#The percentage of patients with controlled asthma went from 29.4% to 67.4% at the end of a 12-month study.3
Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting β₂ agonist; pMDI, pressurised metered-dose inhaler
How flutiform® pMDI demonstrates favourable plume characteristics6
flutiform® pMDI 125/5 μg has a slower, less forceful and warmer plume than fluticasone proprionate/ salmeterol pMDI, which may reduce the amount of drug deposition at the back of the throat and lead to improved lung deposition.6
Plume velocity
Mean maximum velocity of flutiform® pMDI plume was 30% slower than the fluticasone propionate/ salmeterol pMDI plume.6
The clinical relevance of these findings has not been established.
Adapted from Johal B, et al. 2015
Data from an in vitro study; mean maximum velocities (from three readings) observed across the three distances measured. Statistical analyses were not performed for these data.6
Abbreviation: pMDI, pressurised metered-dose inhaler
flutiform® pMDI delivers high fine particle fraction12
flutiform® pMDI consistently delivers a high fine particle fraction of ~40% for both ICS and LABA in vitro regardless of inspiratory flow rate.12
Adapted from Johal B, et al. 2015
Aerodynamic particle size distribution was determined for each product using an 8-stage Anderson Cascade Impactor at two inhalation flow rates: 28.3 and 60.0 L/min. Fine particle dose (mass of dose <5.0 μm) and FPF were calculated as a percentage of the labelled dose for the LABA and ICS of each product at both flow rates.12
Abbreviations: DPI, dry powder inhaler; FPF, fine particle fraction; ICS, inhaled corticosteroid; LABA, long-acting β₂ agonist; pMDI, pressurised metered-dose inhaler
Discover the inhaler with three strengths and a colour-coded dose counter
flutiform® pMDI is available in three dosing strengths to meet the patient’s needs5
Learn how to use flutiform® inhaler
Abbreviations: b.i.d., twice daily; pMDI, pressurised metered-dose inhaler
Be in the know
- Receive newsletters with latest updates in asthma management selected by our panel of specialists
- Access training and educational resources
- Get latest updates on products and services offered
- Watch exclusive webinars from industry leading experts on the topics that matter to you
References
- Usmani OS, et al. J Allergy Clin Immunol Prac 2017;5:1378-87.
- Schmidt O, et al. Respir Med 2017;131:166–74.
- Backer V, et al. Ther Adv Respir Dis 2018:12;1-16.
- Papi A, et al. J Aerosol Med Pulm Drug Deliv. 2016;29:346–361.
- flutiform® SmPC. Last updated 13 April 2022. https://www.emcpi.com/pi/26954. Accessed 5 September 2022.
- Johal B, et al. Adv Ther. 2015;32(6):567–79.
- Iwanaga T, et al. Pulm Ther 2017;3:219-231.
- Marwick JA, et al. Am J Respir Crit Care Med. 2009;179:542–8.
- Prasad SVN, et al. J Cell Biol. 2002;158(3):563–75.
- Rossios, et al. Br J Pharmacol 2012;167:775-86.
- Adner M, et al. J Pharmacol Exp Ther. 2010;333:273–80.
- Johal B, et al. Comb Prod Ther. 2013;3:39–51.
®: FLUTIFORM is the Trademark of Jagotec AG used under licence by Mundipharma.
®: The ‘lung’ logo, is a Registered Trademark of Mundipharma.